Your browser doesn't support javascript.
loading
Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.
Espinel-Ingroff, A; Alvarez-Fernandez, M; Cantón, E; Carver, P L; Chen, S C-A; Eschenauer, G; Getsinger, D L; Gonzalez, G M; Govender, N P; Grancini, A; Hanson, K E; Kidd, S E; Klinker, K; Kubin, C J; Kus, J V; Lockhart, S R; Meletiadis, J; Morris, A J; Pelaez, T; Quindós, G; Rodriguez-Iglesias, M; Sánchez-Reus, F; Shoham, S; Wengenack, N L; Borrell Solé, N; Echeverria, J; Esperalba, J; Gómez-G de la Pedrosa, E; García García, I; Linares, M J; Marco, F; Merino, P; Pemán, J; Pérez Del Molino, L; Roselló Mayans, E; Rubio Calvo, C; Ruiz Pérez de Pipaon, M; Yagüe, G; Garcia-Effron, G; Guinea, J; Perlin, D S; Sanguinetti, M; Shields, R; Turnidge, J.
Affiliation
  • Espinel-Ingroff A; VCU Medical Center, Richmond, Virginia, USA avingrof@vcu.edu.
  • Alvarez-Fernandez M; Servicio de Microbiologia, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Cantón E; Unidad de Microbiología del Centro de Investigación, Valencia, Spain.
  • Carver PL; Department of Clinical, Social and Administrative Sciences, University of Michigan College of Pharmacy, and University of Michigan Health System, Ann Arbor, Michigan, USA.
  • Chen SC; Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia.
  • Eschenauer G; Department of Clinical, Social and Administrative Sciences, University of Michigan College of Pharmacy, and University of Michigan Health System, Ann Arbor, Michigan, USA University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Getsinger DL; Stanford University Medical Center, Hospital and Clinics, Palo Alto, California, USA.
  • Gonzalez GM; Universidad Autonóma de Nuevo León, Monterrey, Nuevo León, Mexico.
  • Govender NP; National Institute for Communicable Diseases and University of the Witwatersrand, Johannesburg, South Africa.
  • Grancini A; Microbiology Lab, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
  • Hanson KE; Department of Pathology, The University of Utah, Salt Lake City, Utah, USA.
  • Kidd SE; National Mycology Reference Centre, SA Pathology, Adelaide, Australia.
  • Klinker K; Department of Pharmacy, UF Health Shands Hospital, Gainesville, Florida, USA.
  • Kubin CJ; Department of Pharmacy, New York Presbyterian Hospital, New York, New York, USA.
  • Kus JV; Public Health Ontario, Toronto, Canada.
  • Lockhart SR; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Meletiadis J; University of Athens, Athens, Greece.
  • Morris AJ; Clinical Microbiology Laboratory, Auckland City Hospital, Auckland, New Zealand.
  • Pelaez T; Hospital General Universitario Gregorio Maranón, Facultad de Medicina-Universidad Complutense, Madrid, Spain.
  • Quindós G; UFI 11/25, Universidad del País Vasco-Euskal Herriko Unibertsitatea, Bilbao, Spain.
  • Rodriguez-Iglesias M; Hospital Universitario Puerta del Mar, Cádiz, Spain.
  • Sánchez-Reus F; Servei de Microbiologia Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Shoham S; Department of Medicine, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
  • Wengenack NL; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Borrell Solé N; Hospital Universitario Son Dureta, Palma de Mallorca, Spain.
  • Echeverria J; Hospital Donostia, San Sebastián, Spain.
  • Esperalba J; Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
  • Gómez-G de la Pedrosa E; Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • García García I; Hospital Universitario de Salamanca, Salamanca, Spain.
  • Linares MJ; Facultad de Medicina, Universidad de Córdoba, Hospital General Universitario Reina Sofía, Córdoba, Spain.
  • Marco F; Department of Microbiology, ISGlobal, Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Merino P; Hospital Clínico Universitario de San Carlos, Madrid, Spain.
  • Pemán J; Hospital Universitario La Fe, Valencia, Spain.
  • Pérez Del Molino L; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
  • Roselló Mayans E; Hospital Universitario Valle Hebrón, Barcelona, Spain.
  • Rubio Calvo C; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Ruiz Pérez de Pipaon M; Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Yagüe G; Hospital Universitario Virgen De La Arrixaca, Murcia, Spain.
  • Garcia-Effron G; Mycology and Molecular Diagnosis Laboratory, Universidad Nacional del Litoral-CONICET, Santa Fe, Argentina.
  • Guinea J; Hospital General Universitario Gregorio Maranón, Facultad de Medicina-Universidad Complutense, Madrid, Spain.
  • Perlin DS; Public Health Research Institute, New Jersey Medical School-Rutgers, Newark, New Jersey, USA.
  • Sanguinetti M; Institute of Microbiology and Institute of Hygiene d'Universita Cattolica del Sacro Cuore, Rome, Italy.
  • Shields R; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Turnidge J; University of Adelaide, Adelaide, Australia.
Antimicrob Agents Chemother ; 59(11): 6725-32, 2015 Nov.
Article in En | MEDLINE | ID: mdl-26282428
ABSTRACT
Neither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established for Candida spp. with anidulafungin, caspofungin, and micafungin when using the Sensititre YeastOne (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable. Candida species wild-type (WT) MIC distributions (for microorganisms in a species/drug combination with no detectable phenotypic resistance) were established for 6,007 Candida albicans, 186 C. dubliniensis, 3,188 C. glabrata complex, 119 C. guilliermondii, 493 C. krusei, 205 C. lusitaniae, 3,136 C. parapsilosis complex, and 1,016 C. tropicalis isolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO ECVs. ECVs for anidulafungin, caspofungin, and micafungin encompassing ≥97.5% of the statistically modeled population were, respectively, 0.12, 0.25, and 0.06 µg/ml for C. albicans, 0.12, 0.25, and 0.03 µg/ml for C. glabrata complex, 4, 2, and 4 µg/ml for C. parapsilosis complex, 0.5, 0.25, and 0.06 µg/ml for C. tropicalis, 0.25, 1, and 0.25 µg/ml for C. krusei, 0.25, 1, and 0.12 µg/ml for C. lusitaniae, 4, 2, and 2 µg/ml for C. guilliermondii, and 0.25, 0.25, and 0.12 µg/ml for C. dubliniensis. Species-specific SYO ECVs for anidulafungin, caspofungin, and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81 Candida isolates with identified fks mutations. SYO ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin, and especially caspofungin, since testing the susceptibilities of Candida spp. to caspofungin by reference methodologies is not recommended.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Candida / Echinocandins / Lipopeptides / Antifungal Agents Type of study: Clinical_trials / Diagnostic_studies Language: En Journal: Antimicrob Agents Chemother Year: 2015 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Candida / Echinocandins / Lipopeptides / Antifungal Agents Type of study: Clinical_trials / Diagnostic_studies Language: En Journal: Antimicrob Agents Chemother Year: 2015 Document type: Article Affiliation country: Estados Unidos